Top

Published in:

Open Access 01-02-2009 | Lab Investigation - Human/Animal Tissue

Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to γ-radiation

Authors: Anne Katrin Schauff, Ella L. Kim, Jan Leppert, Roger Nadrowitz, Robin Wuestenberg, Mark Alexander Brockmann, Alf Giese

Published in: Journal of Neuro-Oncology | Issue 3/2009

Abstract

The invasion- and apoptosis-associated thromboxane synthase gene encoding an enzyme of the arachidonic acid pathway has been implicated in glioma progression. Furegrelate, a specific inhibitor of thromboxane synthase, blocks cell motility, induces apoptosis and increases sensitivity to drug induced apoptosis in human glioma cells in vitro. The impact of furegrelate on the sensitivity of human glioma cells to γ-irradiation was analyzed using colony formation assay in vitro and an orthotopic mouse model in vivo. Pre-treatment of glioma cells with furegrelate increases radiation sensitivity of cultured glioma cells. Treatment of experimental gliomas with suboptimal doses of radiation and furegrelate results in a significant decrease in tumor volumes compared to untreated controls. Thus, the specific thromboxane synthase inhibitor furegrelate increases death response induced by γ-radiation in glioma cells in vitro and sensitizes experimental gliomas to radiation treatment in vivo.

Bennett A (1986) The production of prostanoids in human cancers, and their implications for tumor progression. Prog Lipid Res 25:539–542. doi:10.1016/0163-7827(86)90109-8 PubMedCrossRef

Giese A, Hagel C, Kim EL et al (1999) Thromboxane synthase regulates the migratory phenotype of human glioma cells. Neuro-oncol 1:3–13. doi:10.1215/15228517-1-1-3 PubMedCrossRef

Kürzel F, Hagel C, Zapf S et al (2002) Cyclooxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, proliferation, and apoptosis in human glioma cells. Acta Neurochir (Wien) 144:71–87. doi:10.1007/s701-002-8276-9 CrossRef

Pradono P, Tazawa R, Maemondo M et al (2002) Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62:63–66PubMed

McDonough W, Tran N, Giese A et al (1998) Altered gene expression in human astrocytoma cells selected for migration. I. Thromboxane synthase. J Neuropathol Exp Neurol 55:449–455. doi:10.1097/00005072-199805000-00008 CrossRef

Rodrigues S, Nguyen QD, Faivre S et al (2001) Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J 15:1517–1528. doi:10.1096/fj.00-0802com PubMedCrossRef

Yoshizato K, Zapf S, Westphal M et al (2002) Thromboxane synthase inhibitors induces apoptosis in migration arrested glioma cells. Neurosurgery 50:343–354. doi:10.1097/00006123-200202000-00021 PubMedCrossRef

Kim EL, Meissner H, Warneke G et al (2003) Regulation of thromboxane synthase by tumor suppressor p53 and ets-1. Oncogene 22:7716–7727. doi:10.1038/sj.onc.1207155 PubMedCrossRef

Giese A, Rief MD, Loo MA et al (1994) Determinants of human astrocytoma migration. Cancer Res 54:3897–3904PubMed

10.

Jantke J, Kim E, Kürzel F et al (2004) Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis. Acta Neurochir (Wien) 146:483–494. doi:10.1007/s00701-004-0238-z CrossRef

11.

Aragane Y, Kulms D, Metze D et al (1998) Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol 140:171–182. doi:10.1083/jcb.140.1.171 PubMedCrossRef

12.

Kim EL, Yoshizato K, Meissner H et al (2005) Comparative assessment of status and function of p53 in human glioma cells. Anticancer Res 25:213–224PubMed

13.

Brockmann MA, Westphal M, Lamszus K (2003) Improved method for the intracerebral engraftment of tumour cells and intratumoural treatment using a guide screw system in mice. Acta Neurochir (Wien) 145:777–781. doi:10.1007/s00701-003-0091-5 CrossRef

14.

Brockmann MA, Ulmer S, Leppert J et al (2006) Analysis of mouse brain using a clinical 1.5 Tesla scanner and a standard small loop surface coil. Brain Res 1068:138–142. doi:10.1016/j.brainres.2005.10.098 PubMedCrossRef

15.

Gaffney DK, Holden J, Davis M et al (2001) Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 49:1213–1217. doi:10.1016/S0360-3016(00)01583-2 PubMedCrossRef

16.

Liao Z, Komaki R, Mason KA et al (2003) Role of cyclooxygenase-2 inhibitors in combination with radiation therapy in lung cancer. Clin Lung Cancer 4:356–365PubMedCrossRef

17.

Terakado N, Shintani S, Yano J et al (2004) Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol 40:383–389. doi:10.1016/j.oraloncology.2003.09.005 PubMedCrossRef

18.

Nix P, Lind M, Greenman J et al (2004) Expression of Cox-2 protein in radioresistant laryngeal cancer. Ann Oncol 15:797–801. doi:10.1093/annonc/mdh185 PubMedCrossRef

19.

Milas L (2003) Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis. Am J Clin Oncol 26:66–69

20.

Petersen C, Baumann M, Petersen S (2003) New targets for the modulation of radiation response-selective inhibition of the enzyme cyclooxygenase 2. Curr Med Chem Anticancer Agents 3:354–359. doi:10.2174/1568011033482314 PubMedCrossRef

21.

Liu W, Chen Y, Wang W et al (2003) Combination of radiation and Celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 26:103–109. doi:10.1097/00000421-200306000-00015 CrossRef

22.

Williams CS, Watson AJ, Sheng H et al (2000) Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 60:6045–6051PubMed

23.

Raju U, Nakata E, Yang P et al (2002) In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 54:886–894. doi:10.1016/S0360-3016(02)03023-7 PubMed

24.

Nakata E, Mason KA, Hunter N et al (2004) Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 58:369–375. doi:10.1016/j.ijrobp.2003.09.061 PubMed

25.

Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057–2072. doi:10.1096/fj.01-0390rev PubMedCrossRef

26.

Nie D, Che M, Zacharek A et al (2004) Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am J Pathol 164:429–439PubMed

27.

Moussa O, Yordy JS, Abol-Enein H et al (2005) Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. Cancer Res 65:11581–11587. doi:10.1158/0008-5472.CAN-05-1622 PubMedCrossRef

28.

Watkins G, Douglas-Jones A, Mansel RE et al (2005) Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. Int Semin Surg Oncol 2:23. doi:10.1186/1477-7800-2-23 PubMedCrossRef

29.

Dassesse T, de Leval X, de Leval L et al (2006) Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage. Eur Urol 50:1021–1031. doi:10.1016/j.eururo.2006.01.036 PubMedCrossRef

30.

Sakai H, Suzuki T, Takahashi Y et al (2006) Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS Lett 580:3368–3374. doi:10.1016/j.febslet.2006.05.007 PubMedCrossRef

31.

Reardon DA, Rich JN, Friedman HS et al (2006) Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24:1253–1265. doi:10.1200/JCO.2005.04.5302 PubMedCrossRef

32.

Dittmer J (2003) The biology of the Ets1 proto-oncogene. Mol Cancer 2:29. doi:10.1186/1476-4598-2-29 PubMedCrossRef

33.

Gilliland DG et al (2001) The diverse roles of the ets family of transcription factor in cancer. Clin Cancer Res 7:451–453PubMed

34.

Oikawa T (2004) ETS transcription factors: possible targets for cancer therapy. Cancer Sci 95:626–633. doi:10.1111/j.1349-7006.2004.tb03320.x PubMedCrossRef

Title: Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to γ-radiation
Authors: Anne Katrin Schauff
Ella L. Kim
Jan Leppert
Roger Nadrowitz
Robin Wuestenberg
Mark Alexander Brockmann
Alf Giese
Publication date: 01-02-2009
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2009
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-008-9708-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to γ-radiation

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study

Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C

A role for the p53 pathway in the pathology of meningiomas with NF2 loss

DNA alkylation products formed by 1-(2-chloroethyl)-1-nitrosourea as molecular dosimeters of therapeutic response

Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM

Histone acetylation resulting in resistance to methotrexate in choroid plexus cells